

Message

From: Newhouse, Kathleen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=5F019C8179304045ACD61BC05B571FB0-NEWHOUSE, KATHLEEN]
Sent: 3/23/2016 6:57:34 PM
To: Subramaniam, Ravi [Subramaniam.Ravi@epa.gov]
Subject: FW: BaP-Interspecies scaling for inhalation unit risk

Looks like I forgot to include you on this. Any thoughts on this comment?

From: Newhouse, Kathleen
Sent: Monday, February 08, 2016 1:48 PM
To: Stanek, John <Stanek.John@epa.gov>
Cc: Hogan, Karen <hogan.karen@epa.gov>
Subject: BaP-Interspecies scaling for inhalation unit risk

Hi John, thanks so much for your feedback Ex. 5 Deliberative Process (DP),

— Once I mold it into our comment and response format, I will send it back to you to make sure I didn't murder the intent of it. (This probably won't be for a few weeks.)

Switching gears a bit, I ran across an SAB comment on the inhalation unit risk for BaP that Karen Hogan and I are not sure how to approach. We thought you might have some insight. Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Below I've listed some relevant text from the Tox Review along with the SAB comment we are struggling to address:

Ex. 5 Deliberative Process (DP)

Any thoughts on this?

Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Kathleen Newhouse, MS, DABT

Acting Associate for Chemical Assessment | Toxic Effects Branch | IRIS Division

National Center for Environmental Assessment | Office of Research and Development

U.S. Environmental Protection Agency

Physical location: EPA Region X | M/S OEA-095 office #14J14 | 1200 Sixth Ave Suite 1400 | Seattle, Wa 98101

206-553-1586 (Office: Tue, Thurs, Fri)

Ex. 6 Personal Privacy (PP) (AWL: Mon, Wed)